nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-9775D810·Framework v5.10·Pipeline v0.4·Evaluated 19 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Infectious Diseases·Basis: Full text·Type: Observational cohort study

Cognitive outcome in relation to cerebrospinal fluid markers of neuronal and glial cell damage: A prospective study of tick-borne encephalitis.

2026·Ticks and Tick-borne Diseases·10.1016/j.ttbdis.2026.102673 ↗

Primary claim

CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment.

Tentative · exploratory observational evidence without a formal comparative test establishing GFAP superiority
In brief

Acute CSF GFAP emerges as a candidate marker of later cognitive impairment after tick-borne encephalitis, but the evidence remains exploratory.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

OBJECTIVES: Tick-borne encephalitis (TBE) often results in long-term cognitive sequelae. While biomarkers of neuronal and glial injury are established in other neurological conditions, their role in predicting cognitive outcomes in TBE remains unclear. This study investigated whether acute-phase levels of neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and S100B (calcium-binding protein B) in both cerebrospinal fluid (CSF) and serum, and tau and chitinase-3-like protein 1 (YKL-40) in CSF only, were associated with cognitive functioning at follow-up. METHODS: Ninety-two adults with TBE were recruited in Sweden and Lithuania. CSF and serum samples were collected within 14 days of symptom onset. Neuropsychological testing covering seven cognitive domains was performed six months post-discharge. Raw scores were converted into age- and education-adjusted T-scores; cognitive impairment (CI) was defined as T≤35 on ≥ one test. Group comparisons, correlation analyses, and logistic regressions were conducted, adjusting for age, education, and time-to-testing. ROC analysis evaluated biomarker predictive utility. RESULTS: CI was common, particularly affecting verbal working memory and processing speed. Patients with CI were older and had lower education. GFAP and S100B CSF concentrations were significantly higher in the CI group. GFAP, S100B, and tau correlated with poorer performance, especially in psychomotor speed. However, only CSF GFAP remained a significant predictor of CI after adjustment for age, education, and time-to-testing. In ROC analysis, CSF GFAP displayed high specificity (83%) but low sensitivity (35%). CONCLUSION: CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment.

Key Claims

Primary finding · Tentative

CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment.

Fragile — the claim's weakest requirement is that the effect exists at all. Based on how the study was designed and conducted, not on statistics extracted from the paper. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

exploratory observational evidence without a formal comparative test establishing GFAP superiority

Abstract, Conclusion
Quote verified
Secondary · Tentative

only CSF GFAP remained a significant predictor of CI after adjustment for age, education, and time-to-testing.

small exploratory cohort with correlation-selected biomarkers and a marginal adjusted result among uncorrected tests

Abstract, Results; Table 4
Quote verified
Secondary · Tentative

In ROC analysis, CSF GFAP displayed high specificity (83%) but low sensitivity (35%).

predictive performance estimated in a small exploratory cohort without independent validation

Abstract, Results
Quote verified
Secondary · Supported

CI was common, particularly affecting verbal working memory and processing speed.

descriptive cohort findings under a sensitive one-test impairment definition without matched controls

Abstract, Results; Fig. 1
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#methodological rigour

Prospective sampling precedes later cognitive assessment

Acute CSF and serum sampling precedes follow-up cognitive testing, providing the temporal structure needed to study prognostic associations. Assays were conducted in a single batch with reported intra-assay variation below 10%.

↳ Methods §§2.1–2.3

#contribution

New cognitive outcome link for GFAP

The study extends earlier TBE severity-biomarker work by examining later cognitive outcomes. CSF GFAP retains a nominally significant association after adjustment for age, education, and time-to-testing.

↳ Introduction; Table 4; Discussion

#positioning

Limitations connected to cautious clinical interpretation

The discussion addresses test-version differences, the sensitive impairment definition, biomarker timing, and multiple exploratory analyses. It also distinguishes a possible risk marker from a rule-out test given the low sensitivity.

↳ Discussion, limitations and predictive-utility paragraphs

Limitations

#methodological rigour

Multiple testing leaves the central signal fragile

Numerous biomarker–domain correlations and subsequent models are evaluated without multiplicity control. The only significant adjusted association has p=.04 and a confidence interval of 1.05–4.07.

↳ Methods §2.7; Tables 3–4

#methodological rigour

Sensitive impairment definition lacks robustness checks

Impairment on any one completed test defines the binary outcome, without a matched control group or analyses using more conservative definitions. This limits interpretation of both prevalence and the biomarker association.

↳ Methods §§2.3–2.4; Discussion, limitations

#reporting

Headline superiority exceeds the reported comparison

The Abstract describes GFAP as having the strongest association, but no formal head-to-head comparison establishes that it outperforms the other biomarkers. Being the only adjusted result below p=.05 does not establish superiority.

↳ Abstract, Conclusion; Table 4

Does this match your read? Add your assessment ↓

Nabu Commentary

Prospective acute sampling, standardized cognitive scores, and adjusted models provide a basis for studying later cognitive outcomes. Table 4 identifies a CSF GFAP association with an adjusted odds ratio of 2.07, but its confidence interval of 1.05–4.07 and the uncorrected exploratory analyses make the finding hypothesis-generating. The sensitive one-test impairment definition and lack of alternative-definition analyses further limit robustness. The discussion generally acknowledges these constraints, although the Abstract's claim of the strongest association exceeds the comparative evidence.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.2±0.2

Contribution
3.3

The study extends acute-severity biomarker research by linking acute CSF GFAP to later cognitive outcome in TBE. The advance is incremental because it rests on one exploratory adjusted association in a modest cohort with partial overlap with previous cognitive-outcome work.

Introduction; Table 4; Discussion
Methodological Rigour
3.0

Prospective sampling, batched assays, standardized cognitive scores, and demographic adjustment support the design. Uncorrected multiple testing, correlation-based biomarker selection, a sensitive binary outcome without alternative-definition analyses, and unvalidated predictive performance introduce meaningful uncertainty.

Methods §§2.1–2.4 and 2.7; Tables 3–4; Discussion
Reporting
3.3

The analyses and findings are readily traceable, and the low sensitivity is explicitly reported. The headline comparative claim exceeds what the models establish, reducing the score despite otherwise clear presentation.

Abstract, Results and Conclusion; Table 4; Discussion

"CSF GFAP showed the strongest association"

Positioning
3.7

The paper distinguishes previous severity-biomarker and cognitive-outcome studies, discloses cohort overlap, and relates the findings to other neurological conditions. Its discussion connects measurement, timing, outcome-definition, and multiplicity limitations to a call for replication.

Introduction; Discussion

Reliability

Caveats4 of 4 checks


Results checkNoted
  • CSF GFAP showed the strongest association with long-term cognitive outcome and may reflect astrocytic activation related to persistent cognitive impairment: "CSF and serum samples were collected within 14 days of symptom onset" (Abstract, Methods) vs "availability of paired CSF and serum samples within 14 days of" (Section 2.1 Participants). The Abstract anchors the 14-day window to symptom onset, whereas Methods §2.1 and Table 1 anchor sampling to hospitalization or admission, leaving onset-to-sampling time unresolved. → Effect on result unclear
  • CI was common, particularly affecting verbal working memory and processing speed: "Cognitive impairment at follow-up 92 59 62" (Table 1, Cognitive impairment at follow-up row). 59 divided by 92 multiplied by 100 equals 64.13%, which rounds to 64%, not the reported 62%. → Conclusion holds
Reporting and transparencyNoted

Ethics approval, consent, competing interests, and consent-based restrictions on data sharing are declared. The pooled-cohort discussion reports a country difference in severity without presenting the underlying analysis.

Conflict of interest: declared · Ethics approval: declared · Data availability: not stated

Reference IntegrityClean

32 references in manuscript 29 of 30 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 19 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Infection · Encephalitis
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesMedium
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on an exploratory observational association in a single prospective cohort that the authors say needs replication in independent cohorts.

From the paper
“Clinicians should be mindful that TBE-related cognitive sequelae frequently affect processing speed, learning, and verbal working memory.”

The paper names clinicians as the actors who should apply the findings about affected cognitive domains in TBE follow-up care.

Pathway

Clinicians managing acute TBE could use CSF GFAP as a risk marker to identify patients needing neuropsychological follow-up and rehabilitation after discharge.

Barrier

The exploratory single-cohort design, modest sample, and CSF GFAP's low sensitivity (35%) mean the association must be replicated in independent cohorts before clinical use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Dexamethasone in Hospitalized Patients with Covid-19

    RECOVERY Collaborative Group, Horby, Lim, et al. · 2020 · Clinical medicine

    Primary claim

    Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001).

    Well-supported
    Evidence Score
    4.3±0.2
    Reliability
    Caveats
  2. Maternal Angiotensin Increases Placental Leptin in Early Gestation via an Alternative Renin-Angiotensin System Pathway: Suggesting a Link to Preeclampsia

    Olivia Nonn, Cornelius Fischer, Sabrina Geisberger, et al. · 2021 · Basic medicine

    Primary claim

    Ang IV decreases trophoblastic mitochondrial respiration and increases placental leptin via placental LNPEP.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  3. Placental physioxia is based on spatial and temporal variations of placental oxygenation throughout pregnancy

    Berthold Huppertz · 2023 · Basic medicine

    Primary claim

    In early-onset preeclampsia cases, all in vivo data available today point to increased oxygen values in the intervillous space of the placenta.

    Tentative
    Evidence Score
    2.4±0.2
    Reliability
    Caveats

How the rubric works →